RVNC Overview
Upcoming Projects (RVNC)
-
Don’t see a project related to the company you care about? Create your own!
Executed Projects (RVNC)
-
Quarterly Survey: Frown Line Treatments with a focus on Revance's Daxxify October 2024
Tickers: RVNC, ABBV, EOLS, Galderma, Merz Aesthetics, Crown Laboratories
Executed On: Oct 22, 2024 at 12:05 PM EDT -
Quarterly Survey: Frown Line Treatments with a focus on Revance's Daxxify July 2024
Tickers: RVNC, ABBV, EOLS, Galderma, Merz Aesthetics
Executed On: Jul 26, 2024 at 12:20 PM EDT -
Discussing the use of Revance’s DAXXIFY for the treatment of Cervical Dystonia with a current prescriber
Ticker: RVNC
Executed On: Jun 07, 2024 at 03:00 PM EDT -
Quarterly Survey: Frown Line Treatments with a focus on Revance's Daxxify April 2024
Tickers: RVNC, ABBV, EOLS, Galderma, Merz Aesthetics
Executed On: Apr 18, 2024 at 12:52 PM EDT -
Quarterly Survey: Frown Line Treatments with a focus on Revance's Daxxify January 2024
Tickers: RVNC, ABBV, EOLS, Galderma, Merz Aesthetics
Executed On: Jan 19, 2024 at 10:48 AM EST -
Quarterly Survey: Frown Line Treatments with a focus on Revance's Daxxify October 2023
Tickers: RVNC, ABBV
Executed On: Oct 31, 2023 at 12:02 PM EDT -
Discussing the recent FDA approval and potential of Revance’s DAXXIFY, an injection for the treatment of Cervical Dystonia
Ticker: RVNC
Executed On: Aug 24, 2023 at 11:30 AM EDT -
Quarterly Survey: Frown Line Treatments with a focus on Revance's Daxxify July 2023
Tickers: RVNC, ABBV, IPN, EOLS
Executed On: Jul 31, 2023 at 03:46 PM EDT -
Quarterly Survey: Frown Line Treatments with a focus on Revance's Daxxify April 2023
Tickers: RVNC, ABBV, IPN
Executed On: Apr 19, 2023 at 12:15 PM EDT -
Quarterly Survey: Frown Line Treatments with a focus on Revance's Daxxify January 2023
Tickers: RVNC, ABBV, IPN
Executed On: Feb 14, 2023 at 12:43 PM EST -
Examining a clinician's confidence in botox biosimilar clinical development programs
Tickers: VTRSV, AGN, RVNC
Executed On: Oct 14, 2022 at 08:30 AM EDT
Expired Projects (RVNC)
-
Discussing Revance Therapeutics’ DaxibotulinumtoxinA in Moderate to severe glabellar lines following PDUFA Approval
Ticker: RVNC
Execute By: Nov 17, 2022
Upcoming & Overdue Catalysts (RVNC)
-
Don’t see a catalyst related to the company you care about? Create your own!
Occurred Catalysts (RVNC)
-
Revance's (RVNC) DAXI (RT002) - (ASPEN-1/ASPEN-OLS) in Cervical dystonia data to be presented at AAN meeting April 17-22, 2021
Ticker: RVNC
Occurred on: Apr 17, 2021 -
Revance's (RVNC) RT002 data from Pivotal SAKURA Phase 3 Trials for Glabellar Lines released
Ticker: RVNC
Occurred on: Dec 05, 2017 -
Revance Reports Results for RT001 Topical Phase 3 Trial for Lateral Canthal Lines
Ticker: RVNC
Occurred on: Jun 13, 2016 -
Phase 2 trial of RT001 for Hyperhidrosis to be completed 1Q 2016. Larger Phase 2 trial planned for 2016
Ticker: RVNC
Occurred on: Mar 02, 2016 -
Revance's (RVNC) RT002 Superior to Allergan's (AGN) BOTOX in Phase 2 Study Evaluating Treatment of Frown Lines
Tickers: RVNC, PFE, VRX, AGN
Occurred on: Oct 29, 2015
Strategic Initiatives (RVNC)
-
Don’t see a strategic initiative related to the company you care about? Create your own!
